Cameco: The Stock That Misses on Earnings and Rips 7% Anyway

# Cameco: The Stock That Misses on Earnings and Rips 7% Anyway

There's a certain kind of stock where the earnings number stops mattering, and Cameco just crossed that threshold. On July 31, CCJ reported a Q2 that missed earnings estimates by 50%. Fifty percent. In a normal world, that's the kind of print that gets a stock cut in half by lunchtime. Instead, shares jumped 7%. Welcome to trading the nuclear renaissance, where the story is bigger than the quarter.

The miss that wasn't a miss

Let's be fair to the number: the earnings collapse wasn't really about uranium. Revenue actually beat, coming in 10% above consensus, and realized uranium and fuel services prices kept strengthening. The hole in the earnings came from lower Westinghouse equity income and the timing of sales volumes — lumpy, non-core-operations noise, not a crack in the thesis. The market seemed to agree, choosing to look past the accounting mess and focus on three things: full-year guidance held, Westinghouse IPO plans got teased, and the nuclear demand story is still very much alive.

That's the trade right now. Cameco has become a "narrative stock" wearing a commodity producer's clothes — and when the narrative is intact, a bad quarter is just noise.

Cigar Lake: the plot twist that resolved fine

The scarier part of the last month wasn't the earnings — it was Cigar Lake. Cameco's flagship, highest-grade Saskatchewan mine had a temporary production suspension, and the stock puked accordingly: a 17.6% slide from roughly $106 to $88 over 30 days. That's the kind of drawdown that should make you nervous about concentration risk, because Cigar Lake isn't just a mine for Cameco — it's practically the mine.

But production resumed, 2026 output guidance held, and the stock snapped back 3.2% on the news. Cameco also quietly strengthened its ownership stake in the asset. So the disruption turned into a buying opportunity rather than a thesis-breaker — this time. File that under "resolved, not resolved forever." Single-asset concentration risk doesn't go away just because this particular scare passed.

The bull case, in one sentence

Uranium supply is structurally tight, Cameco has deliberately kept production disciplined rather than chasing volume, it's got 28+ million pounds annually contracted for five years, and it sits on Westinghouse — AP1000 optionality plus a looming IPO that could unlock real value. Layer on bipartisan-friendly policy tailwinds (the Russian uranium import ban, the Nuclear Fuel Security Act) and you get a stock that's less "uranium miner" and more "levered call option on the West re-industrializing its nuclear fuel chain." That's a genuinely good story. It's also a story the market has clearly already started pricing in.

The problem: you're paying up for the story

Here's where I get less enthusiastic. This is a stock with a P/E north of 160 and a PEG near 1.8, trading with revenue actually down nearly 2% year-to-date and operating margins compressing to 9.1%. The balance sheet is genuinely strong — $11B in cash, low leverage — but that's a fortress built to survive volatility, not evidence the current price is cheap. Barclays trimmed its target to $97. Fintel cut its number by nearly 29%, landing around $124. A board departure (safety committee chair Dominique Minière stepping down) adds a small but real governance wrinkle nobody's talking about.

Technically, the stock is fighting it out in a range — support in the high-$80s to low-$90s, resistance near $100 — which tells you the market itself hasn't decided whether this is a buy-the-dip name or a stock searching for a floor.

The congressional angle, because of course

Lawmakers have been net buyers — 15 buys versus 9 sells across recent disclosures — clustering around the exact window when the stock was cheapest post-selloff and policy momentum (the Russian import ban, nuclear incentives) was building. Draw your own conclusions about information asymmetry, but the pattern is a decent proxy for "smart money thinks the policy tailwind is real."

Bottom line

Cameco is a high-conviction, high-beta wager on nuclear power finally getting the capital cycle it's deserved for a decade — and the fundamentals of that story (contracted volumes, tight supply, Westinghouse optionality) are legitimately strong. But you're not buying it cheap; you're buying the momentum and the narrative at a valuation that has zero room for another Cigar Lake-style scare. Base case sits around $100, bull case near $127, bear case at $87 — which tells you this is a stock where the range itself is the risk. Own it if you believe in the multi-year nuclear buildout and can stomach 15-20% drawdowns on operational hiccups. Don't own it expecting the earnings to make sense quarter to quarter — they won't, and apparently, the market doesn't care.